Inv(3) Acute Myeloid Leukemia in a Young Adult and Review of the Literature
Carlee Blakemore1, Sudarshawn Damodharan1,2, Diane Puccetti1,2
1Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
Abstract:
Acute myeloid leukemia (AML) with the high-risk variant inv(3)/t(3;3) or t(3;3)(q21;26.2) is rarely seen in the pediatric and young adult population. It is associated with poor outcomes with ineffective therapeutic options. Here, we present a case of an 18-year-old female with treatment refractory inv(3) AML in whom remission was unable to be obtained. Better treatment options are needed given the increased resistance to traditional therapy this subtype portrays. Here, we review the literature on pediatric and young adult inv(3) AML along with newer therapeutic options.
Insights
Pediatric and young adult acute myeloid leukemia (AML) with the inv(3) or t(3;3) variant is rare and has poor outcomes. This case highlights the urgent need for better therapeutic options due to treatment resistance.
Area of Science:
- Hematology
- Pediatric Oncology
- Genetics
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- The inv(3)/t(3;3) chromosomal abnormality is a rare but high-risk subtype of AML.
- This variant is particularly challenging in pediatric and young adult patients.
Observation:
- A case of an 18-year-old female with treatment-refractory inv(3) AML is presented.
- The patient was unable to achieve remission with standard therapies.
- This highlights the aggressive nature and therapeutic resistance of this AML subtype.
Findings:
- Inv(3)/t(3;3) AML in young individuals is associated with poor prognosis.
- Traditional chemotherapy options are often ineffective against this specific genetic alteration.
- Limited therapeutic strategies exist for this rare pediatric and young adult AML variant.
Implications:
- There is a critical need for novel and more effective treatment strategies for pediatric and young adult inv(3)/t(3;3) AML.
- Further research into the molecular mechanisms driving treatment resistance is warranted.
- Exploring newer therapeutic avenues may improve outcomes for this challenging patient population.
